Skip to content
DataLookout
Menu

NCT07892274

Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer

StatusNot Yet Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Progression-Free Survival (PFS)
Timeframe: 24 months

Secondary (7)

Overall Survival (OS)
Objective response rate (ORR)
Clinical Benefit Rate (CBR)
FACT-B
QLQ-BR23
Show 2 moreShow less
Incidence of adverse events(AE)
Biomarkers and treatment sensitivity analysis

Arms and interventions

Fulvestrant + Pyrotinib + DalpiciclibExperimental
Trastuzumab RezetecanActive comparator

Drugs: Fulvestrant, Pyrotinib, Dalpiciclib, Trastuzumab Rezetecan

Sites

1 site in 1 country

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhou, Guangdong, China